Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PfizerfiledCriticalPfizer
Priority to DO2005000093ApriorityCriticalpatent/DOP2005000093A/en
Publication of DOP2005000093ApublicationCriticalpatent/DOP2005000093A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención proporciona compuestos de fórmula (I), que son una clase de agonistas de dopamina, más particularmente una clase de agonistas que son selectivos por D3 frente a D2. Estos compuestos son útiles para el tratamiento y/o la prevención de disfunción sexual, por ejemplo, disfunción sexual femenina (DSF), en particular trastomo de la excitación sexual femenina (TESF), trastorno del deseo sexual hipoactivo (TDSH, falta de interés en el sexo), trastomo orgásmico femenino (TOF, incapacidad de alcanzar el orgasmo) y disfunción sexual masculina, particularmente disfunción eréctil masculina (DEM). La disfunción sexual masculina como se designa en la presente memoria se pretende que incluya trastornos eyaculatorios tales como eyaculación precoz, anorgasmia (incapacidad de conseguir el orgasmo) otrastornos del deseo tales como trastorno del deseo sexual hipoactivo (TDSH, falta de interés en el sexo). Estos compuestos son también útiles para tratar trastornos neuropsiquiádtricos y trastomos neurodegenerativos.The present invention provides compounds of formula (I), which are a class of dopamine agonists, more particularly a class of agonists that are selective for D3 versus D2. These compounds are useful for the treatment and / or prevention of sexual dysfunction, for example, female sexual dysfunction (DSF), in particular female sexual arousal disorder (TESF), hypoactive sexual desire disorder (TDSH, lack of interest in sex), female orgasmic disorder (TOF, inability to reach orgasm) and male sexual dysfunction, particularly male erectile dysfunction (DEM). Male sexual dysfunction as designated herein is intended to include ejaculatory disorders such as premature ejaculation, anorgasmia (inability to achieve orgasm) or other desire disorders such as hypoactive sexual desire disorder (TDSH, lack of interest in sex) . These compounds are also useful for treating neuropsychiatric disorders and neurodegenerative disorders.
DO2005000093A2005-05-202005-05-20
NEW DERIVATIVES OF INDAZOL AND INDOLONA AND ITS USE AS PHARMACEUTICAL PRODUCTS
DOP2005000093A
(en)
Compounds derived from 2h-pyrazole [3,4-c] -quinoline, 2h-pyrazol [3,4-c] [1,5 or 1,7] -naphthyridine and 2h-benzo [b] [1,4] - Oxazine, its pharmaceutical compositions useful for the treatment of diseases and disorders of the respiratory system, systemic anaphylaxis or hypersensitivity responses among others.
Compounds derived from heteroaryl-cyclohexyl-tetraazabenzo (e) substituted azanes, vasopressin v1a receptor modulators; preparation procedure; pharmaceutical composition; and its use for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, anxiety, among others.
Combination of 0.1 to 1 mg of at least one sgc stimulator selected from a defined group with 2.5 to 20 mg of a pde5 inhibitor selected from another group; Pharmaceutical formulation that includes and uses it in the treatment of male sexual dysfunction.
Compounds derived from substituted heterobaryl-cyclohexyl-tetraazabenzo [e], modular vasopressin v1a receptor; preparation procedure; pharmaceutical composition; and its use for the prevention or treatment of dysmenorrhea, male or female sexual dysfunction, anxiety, hypertension, among others.
Compounds derived from 1,2-disubstituted heterocycles and bicycles that always comprise a phenyl cycle as the main substituent, pharmaceutical composition; use of the pharmaceutical composition in the treatment of disorders of the central nervous system, such as eating, sexual, sleep disorders, diabetes, among others.